(1R,4R)-Methyl 4-formylcyclohexanecarboxylate | 54274-80-5

• 物质功能分类: 医药中间体 - 原料药中间体
• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (1R,4R)-Methyl 4-formylcyclohexanecarboxylate
• 英文别名: trans-4-formyl-cyclohexanecarboxylic acid methyl ester；trans-4-formylcyclohexanecarboxylic acid methyl ester；methyl (trans)-4-formylcyclohexane-1-carboxylate；methyl trans-4-formylcyclohexane-1-carboxylate；methyl trans-4-formylcyclohexane carboxylate；methyl trans-4-formylcyclohexanecarboxylate
• CAS: 54274-80-5
• 化学式: C₉H₁₄O₃
• 分子量: 170.208
• InChiKey: LARSGJZNVQJRMD-ZKCHVHJHSA-N

物化性质

• 沸点：
  236.4±33.0 °C(Predicted)
• 密度：
  1.129±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.16
• 重原子数：
  12.0
• 可旋转键数：
  2.0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.78
• 拓扑面积：
  43.37
• 氢给体数：
  0.0
• 氢受体数：
  3.0

安全信息

• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

反应信息

• 作为反应物：
  描述：

  (1R,4R)-Methyl 4-formylcyclohexanecarboxylate 在 甲醇 、 sodium tetrahydroborate 作用下， 以 二氯甲烷 为溶剂， 反应 17.0h， 生成 ((1r,4r)-4-ethynylcyclohexyl)methanol
  参考文献：
  名称：

  WO2024064328A1

  摘要：

  公开号：
• 作为产物：
  描述：

  trans-1-chlorocarbonyl-4-(methoxycarbonyl)-cyclohexane 在 2,6-二甲基吡啶 、 5%-palladium/activated carbon 、 氢气 作用下， 以 甲苯 为溶剂， 20.0~35.0 ℃ 、344.75 kPa 条件下， 生成 (1R,4R)-Methyl 4-formylcyclohexanecarboxylate
  参考文献：
  名称：

  Counterion effects in the preparation of aldehyde–bisulfite adducts

  摘要：

  The identification and development of an aldehyde-bisulfite adduct as an isolable starting material in the synthesis of the CETP inhibitor Evacetrapib are described. The physical properties of the sodium and potassium analogs are compared, and the extension of the scope of this study to include an investigation into the solid state properties of a range of sodium and potassium bisulfite adducts of commonly encountered aldehydes is discussed. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetlet.2013.09.105

文献信息

• HETEROARYL-CYCLOHEXYL-TETRAAZABENZO[E]AZULENES
  申请人：Dolente Cosimo

  公开号：US20110275801A1

  公开（公告）日：2011-11-10

  The present invention provides heteroaryl-cyclohexyl-tetraazabenzo[e]azulenes of formula I wherein R 1 , R 2 and R 3 are as described herein. The compounds according to the invention act as V1a receptor modulators, and in particular as V1a receptor antagonists, their manufacture, pharmaceutical compositions containing them and their use as medicaments. The active compounds of the present invention are useful as therapeutics acting peripherally and centrally in the conditions of dysmenorrhea, male or female sexual dysfunction, hypertension, chronic heart failure, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome, anxiety, depressive disorders, obsessive compulsive disorder, autistic spectrum disorders, schizophrenia, and aggressive behavior.

  本发明提供了式I的杂芳基-环己基-四氮杂苯并[e]氮杂蒽衍生物， 其中R1、R2和R3如本文所述。 根据发明的化合物作为V1a受体的调节剂，尤其是作为V1a受体拮抗剂，它们的制造，含有它们的药物组合物以及它们作为药物的使用。本发明的活性化合物作为治疗剂，在痛经、男性或女性性功能障碍、高血压、慢性心力衰竭、不适当分泌血管升压素、肝硬化、肾病综合征、焦虑、抑郁障碍、强迫症、孤独症谱系障碍、精神分裂症和侵略性行为的条件中，在周围和中心发挥作用。
• [EN] CYCLOHEXYL-4H,6H-5-OXA-2,3,10B-TRIAZA-BENZO[E]AZULENES AS V1A ANTAGONISTS<br/>[FR] CYCLOHEXYL-4H,6H-5-OXA-2,3,10B-TRIAZABENZO[E]AZULÈNES UTILISÉS COMME ANTAGONISTES DES V1A
  申请人：HOFFMANN LA ROCHE

  公开号：WO2013050334A1

  公开（公告）日：2013-04-11

  The present invention provides 4H,6H-5-oxa-2,3,10b-triaza-benzo[e]azulenes, which act as V1a receptor modulators, and in particular as V1a receptor antagonists, their manufacture, pharmaceutical compositions containing them and their use as medicaments. The active compounds of the present invention are useful as therapeutics acting peripherally and centrally in the conditions of dysmenorrhea, male or female sexual dysfunction, hypertension, chronic heart failure, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome, anxiety, depressive disorders, obsessive compulsive disorder, autistic spectrum disorders, schizophrenia, and aggressive behavior.

  本发明提供了4H,6H-5-氧杂-2,3,10b-三唑-苯并[e]吖啶衍生物，它们作为V1a受体调节剂，特别是作为V1a受体拮抗剂，它们的制造方法，含有它们的药物组合物以及它们作为药物的使用。本发明的活性化合物作为治疗剂在末梢和中央条件下对痛经、男性或女性性功能障碍、高血压、慢性心力衰竭、不适当的抗利尿激素分泌、肝硬化、肾病综合征、焦虑、抑郁障碍、强迫症、孤独症谱系障碍、精神分裂症和攻击性行为是有用的。
• I. Discovery of a novel series of CXCR3 antagonists. Multiparametric optimization of N , N -disubstituted benzylamines
  作者：Imre Bata、Zsuzsanna Tömösközi、Péter Buzder-Lantos、Attila Vasas、Gábor Szeleczky、Sándor Bátori、Veronika Barta-Bodor、László Balázs、György G. Ferenczy

  DOI：10.1016/j.bmcl.2016.10.035

  日期：2016.11

  N,N-Disubstituted benzylamine derivatives have been identified as CXCR3 antagonists. Compounds were optimized to improve affinity and selectivity, to increase metabolic stability in human and mouse liver microsomes, to increase Caco-2 permeability. Optimization was supported by monitoring physico-chemical properties using both experimental and computational means. Several compounds with double-digit

  N，N-二取代的苄胺衍生物已被鉴定为CXCR3拮抗剂。优化化合物以改善亲和力和选择性，以增加人和小鼠肝微粒体的代谢稳定性，以增加Caco-2的通透性。通过使用实验和计算手段监测理化性质来支持优化。已鉴定出具有两位数纳摩尔级CXCR3亲和力，良好的选择性，微粒体稳定性，Caco-2通透性和人肝细胞清除率的化合物。
• Methylene C(sp³)–H β,β′-Diarylation of Cyclohexanecarbaldehydes Promoted by a Transient Directing Group and Pyridone Ligand
  作者：Sahra St John-Campbell、Andrew J. P. White、James A. Bull

  DOI：10.1021/acs.orglett.0c00124

  日期：2020.3.6

  A hindered β-amino amide transient directing group effects di-trans-arylation of cyclohexanecarbaldehydes. The amide N-substituents are shown to affect yield and can enhance the rate of arylation compared with the α-amino acid. Addition of a pyridone ligand further enhanced reactivity. The reaction is successful for a range of aryl iodides, and various substituted cyclohexane carboxaldehydes, providing

  受阻的β-氨基酰胺瞬态导向基团可实现环己烷甲醛的双反芳基化作用。与α-氨基酸相比，酰胺N-取代基显示出影响收率并且可以提高芳基化速率。吡啶酮配体的添加进一步增强了反应性。对于一系列的芳基碘化物和各种取代的环己烷甲醛，该反应是成功的，可以从简单的原料中得到官能化的产物。提出了引起瞬态烯胺的机制。
• Cycloalkane carboxylic acid derivatives as CXCR3 receptor antagonists
  申请人：SANOFI

  公开号：EP2601950A1

  公开（公告）日：2013-06-12

  The present invention relates to compounds of formula 1 that are useful as an active ingredient of a medicament for preventive and/or therapeutic treatment of diseases caused by abnormal activation of CXCR3 chemokines. The invention relates furthermore to a process for the preparation of said compounds, to pharmaceutical compositions containing said compounds and to the novel intermediates used in the preparation of said compounds.

  本发明涉及公式1的化合物 它们可用作预防性和/或治疗由CXCR3趋化因子异常激活引起的疾病的药物的活性成分。本发明还涉及制备所述化合物的方法、包含所述化合物的药物组合物以及用于制备所述化合物的新中间体。